Joachim G.J.V. Aerts

Research interests

Publications

• Estimated Global Proportions of Individuals With Persistent Fatigue, Cognitive, and Respiratory Symptom Clusters Following Symptomatic COVID-19 in 2020 and 2021

  JAMA · 2022 · https://doi.org/10.1001/jama.2022.18931

• IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain

  Journal of Thoracic Oncology · 2021 · 10.1016/j.jtho.2021.09.014

• Analyzing high-dimensional cytometry data using FlowSOM

  Nature Protocols · 2021 · 10.1038/s41596-021-00550-0

• Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy

  Journal for ImmunoTherapy of Cancer · 2021 · 10.1136/jitc-2021-002421

• Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial

  New England Journal of Medicine · 2020 · https://doi.org/10.1056/nejmoa1911793

• The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes

  Cancer Cell · 2020 · 10.1016/j.ccell.2020.09.001

• Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials

  The Lancet Respiratory Medicine · 2020 · 10.1016/s2213-2600(20)30391-x

• Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non–Small Cell Lung Cancer

  JAMA Oncology · 2019 · https://doi.org/10.1001/jamaoncol.2019.1478

• Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial

  The Lancet Oncology · 2019 · 10.1016/s1470-2045(19)30532-7

• Lung Cancer Surveillance After Definitive Curative-Intent Therapy: ASCO Guideline

  Journal of Clinical Oncology · 2019 · 10.1200/jco.19.02748

• Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial

  The Lancet Oncology · 2017 · 10.1016/s1470-2045(17)30446-1

• Novel insights into mesothelioma biology and implications for therapy

  Nature reviews. Cancer · 2017 · https://doi.org/10.1038/nrc.2017.42

• Depletion of Tumor-Associated Macrophages with a CSF-1R Kinase Inhibitor Enhances Antitumor Immunity and Survival Induced by DC Immunotherapy

  Cancer Immunology Research · 2017 · 10.1158/2326-6066.cir-16-0309

• Thyroid Function and Cancer Risk: The Rotterdam Study

  The Journal of Clinical Endocrinology & Metabolism · 2016 · 10.1210/jc.2016-2104

• PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non–Small-Cell Lung Cancer

  Journal of Clinical Oncology · 2016 · https://doi.org/10.1200/jco.2015.64.8824

• Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer

  Journal of Clinical Oncology · 2016 · 10.1200/jco.2016.67.6601

• Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

  New England Journal of Medicine · 2015 · https://doi.org/10.1056/nejmoa1504627

• Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial

  The Lancet Respiratory Medicine · 2014 · 10.1016/s2213-2600(14)70019-0

• Maintenance bevacizumab–pemetrexed after first-line cisplatin–pemetrexed–bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial

  Annals of Oncology · 2014 · 10.1093/annonc/mdu098

• Characteristics of Lung Cancers Detected by Computer Tomography Screening in the Randomized NELSON Trial

  American Journal of Respiratory and Critical Care Medicine · 2013 · 10.1164/rccm.201209-1651oc

• Randomized Phase III Trial of Maintenance Bevacizumab With or Without Pemetrexed After First-Line Induction With Bevacizumab, Cisplatin, and Pemetrexed in Advanced Nonsquamous Non–Small-Cell Lung Cancer: AVAPERL (MO22089)

  Journal of Clinical Oncology · 2013 · 10.1200/jco.2012.42.3749

• Tumor-Specific Cytotoxic T Cells Are Crucial for Efficacy of Immunomodulatory Antibodies in Patients with Lung Cancer

  Cancer Research · 2013 · 10.1158/0008-5472.can-12-3932

• COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function

  BMC Cancer · 2010 · 10.1186/1471-2407-10-464

• Gene Expression-Based Classification of Non-Small Cell Lung Carcinomas and Survival Prediction

  PLoS ONE · 2010 · https://doi.org/10.1371/journal.pone.0010312

• Consolidative Dendritic Cell-based Immunotherapy Elicits Cytotoxicity against Malignant Mesothelioma

  American Journal of Respiratory and Critical Care Medicine · 2010 · 10.1164/rccm.200909-1465oc

Current projects

No projects listed.